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This broad-spectrum modulation of host immunity has intended
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disadvantageous. Thus the host can benefit from suppression of
collateral damage during parasite infection and from reduced
allergic, autoimmune, and inflammatory reactions. However,
helminth infection can also be detrimental in reducing vaccine
responses, increasing susceptibility to coinfection and
potentially reducing tumor immunosurveillance. In this review
we will summarize the panoply of immunomodulatory
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Helminths are highly prevalent metazoan worm parasites,
which have evolved a spectrum of sophisticated means to regulate
and evade the host immune system.1 Helminths appear to act as
successful xenotransplants into the mammalian body, neutral-
izing immune pathways that would otherwise expel them and
resetting the thresholds of immune reactivity.2 In so doing, they
also dampen responses to unrelated bystander specificities, such
as allergens and autoantigens, in a manner that might in fact
benefit the host.1,3
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666nearly one third of the human population.4 Their extraordinary
prevalence bears witness to their success at defeating host de-
fenses and suggests we have much to learn from how these para-
sites modulate our own immune system.
Although helminths establish in a range of tissue and intestinal
niches, in nearly all cases they do not multiply within the host but
produce eggs or larvae to infect new hosts; hence they tend to
establish stable chronic infections that can endure for surprisingly
long (up to 20 years) in an individual host. In this setting almost
every facet of the immune system is modified or even recali-
brated, with infected subjects displaying a state of immune
hyporesponsiveness that can be considered a form of immuno-
logic tolerance.5-7IMMUNOLOGIC TOLERANCE IN HUMAN
HELMINTH INFECTIONS
Immunologic hyporesponsiveness in helminth infections was
first seen through muted parasite antigen-specific T-cell re-
sponses, from patients’ PBMC cultures.7-10 In particular, specific
unresponsiveness was seen in asymptomatic carriers rather than
those with progressive pathologic manifestations, such as
elephantiasis. Furthermore, anthelminthic drug clearance of par-
asites from hyporesponsive carriers resulted in a recovery of
antigen-specific responses, suggesting that they were actively in-
hibited by the presence of helminths.10,11 In addition, T cells from
helminth-infected asymptomatic human subjects show skewed
cytokine profiles, favoring IL-4 over IL-17 and IFN-g10 and
with more conspicuous IL-10 and TGF-b components.12,13 In
contrast, in patients in whom symptomatic disease develops, there
is a failure of tolerance, allowing TH1 and TH17 responses to sur-
face and mediate significant pathology in infected tissues.14,15
In the immune system homeostatic tolerance to self-antigens
and harmless environmental antigens (including commensal
bacteria and food components) is primarily maintained by an
immunosuppressive T-cell subset, the regulatory T (Treg) cell.16
As discussed below, a strong link has emerged between long-
term helminth infection and Treg cell activity, particularly in
the asymptomatic or hyporesponsive state.17-19
Immune downregulation by helminths further extends into
many local and systemic settings, withmodulation of responses to
a variety of unrelated bystander specificities.3 One example is that
J ALLERGY CLIN IMMUNOL
VOLUME 138, NUMBER 3
MAIZELS AND MCSORLEY 667polyclonal immune responses to childhood vaccines can be
compromised in heavily infected subjects.20 In addition, hel-
minths can undermine host defenses against other major patho-
gens, such as Mycobacterium tuberculosis.3,21 In the case of
malaria, however, the consequences of helminth infection are
more nuanced, with evidence of increased susceptibility com-
bined with moderated inflammatory responses and hence attenu-
ated disease severity.22,23
The delicate balance between inflammation and immune
regulation is exemplified in cysticercosis, a neurological pathol-
ogy caused by inflammatory responses to Taenia solium cysts.24 It
is well recognized that pathologic inflammation can be dampened
by immunoregulatory mechanisms that might underpin the
asymptomatic phase of disease.25 However, patients with the
most highly disseminated infections actually show the greatest
degree of immunoregulation, with increased IL-10 levels,
decreased TH1 and TH2 cytokine levels, and a trend for increased
Treg cell numbers.26 Thus the immune response to T solium infec-
tion is finely poised: strong immunomodulation leads to dissem-
ination of the parasite, whereas failure to regulate inflammation
causes seizures and death.
Helminth parasites clearly establish hyporesponsiveness in the
naive adult in model systems, but in endemic settings it is
common for offspring to be born to infected mothers, become
infected at a very early age, or both. Maternal infection boosts
tolerance in the newborn, so that offspring of Haitian mothers
with the filarial infection Wuchereria bancrofti were 2- to 3-fold
more likely to become infected themselves while showing a lower
level of T-cell reactivity to parasite antigens than children of un-
infected mothers.27 In a remarkable study in the Cook Islands, it
was confirmed that even at 17 years of age, subjects born to in-
fected mothers mounted substantially weaker T-cell responses
to parasite antigens.28 Hence in the endemic setting it seems
likely that many subjects experience in utero tolerization to para-
site antigens. Furthermore, prenatal exposure also affects
bystander reactivities both in human subjects29 and in experi-
mental models, such as airway allergy.30 As will be discussed
further, anti-inflammatory effects of helminth infection are
observed not only in the setting of allergy but also in the context
of autoimmunity and transplantation reactions.2,31,32Treg CELLS IN HELMINTH INFECTION: FROM THE
FIELD TO THE LABORATORY
A key association has emerged between helminth infection and
expansion of regulatory cell populations, most importantly the
Treg cell subset.17,18,33 In human subjects Treg cells expressing
the transcription factor forkhead box protein 3 (Foxp3) are
more numerous and more active in helminth-infected subjects
but decrease after anthelmintic chemotherapy.19,34,35 In filarial in-
fections patients with pathologies, such as elephantiasis and hy-
perreactive onchocerciasis, show diminished Treg cell levels
compared with those in unresponsive asymptomatic carriers, sup-
porting the argument that the Treg cell compartment both main-
tains tolerance and prevents pathology in these
infections.15,36,37 Likewise, in highly prevalent soil-transmitted
intestinal nematode infections, a similar profile of increased
Treg cell activity, immunosuppressive cytokine production, and
antigen hyporesponsiveness is evident.38,39 Mechanistically, mul-
tiple pathways are implicated in the downregulation of human re-
sponses to helminths, involving the cytokines IL-10 and TGF-b,and cell-surface interactions through cytotoxic T lymphocyte–
associated antigen 4 and programmed death-1.19,38-40
In human subjects the activity of Treg cells and production of IL-
10 correlate closely with an isotype switch from the proallergic/
inflammatory IgE to the noninflammatory IgG4
41; Foxp32 TR1 cell
are the predominant source of IL-10,36 although Foxp31 Treg cells
are also present, and both contribute to driving IgG4 in human sub-
jects.42 Serum IgG4 is largely composed of mixed dimers. Because
the heavy chains lack linking disulfide bonds, they exchange with
other IgG4molecules; suchmixedmolecules are functionallymono-
valent andnoninflammatory.43Drug treatment of patients resulted in
sharp decreases in circulating IgG4 levels, again arguing that para-
sites press the host immune system to favor this isotype.44
The causal links between helminth infections andTreg cells have
now been established in both directions. First, certain helminths
directly drive Treg cell responses from the host45 or do so indirectly
through inducing host cells to produce TGF-b, a key cytokine that
promotes regulatory cell function.46 Hence the expansion of Treg
cells is not simply a corollary of the host inflammatory response
that must accompany it to prevent overreaction.
Second, Treg cells are essential for parasites to survive in the
immunocompetent host because their depletion in mouse model
systems results in clearance of the infection,47-49 whereas expansion
of Treg cells through IL-2 administration rendersmicemore suscep-
tible.49 Interestingly, in the mouse model of filariasis, Treg cells
establish hyporesponsiveness in the effector population, so that
clearance of tissue-dwelling parasites requires not only ablation of
Treg cells but also restimulation of the effector population.50,51
The effects of Treg cells in murine helminth infections also
mirror those in human subjects in other ways. For example, Treg
cells are instrumental in attenuation of allergy in mice infected
with gastrointestinal nematodes52 or schistosomes.53 They also
play a vital role protecting the host from pathology because
Treg cell depletion can exacerbate inflammatory responses with
lethal results.48,49,54 Thus although partial Treg cell depletion
can strengthen the TH2 response required for parasite expulsion,
in their total absence an inflammatory storm prevails, preventing
a coherent protective immune response.49
Treg cells are also implicated in the weakened defenses against
other parasites, and in human subjects in vitro T-cell proliferative
responses to BCG andmalaria are attenuated in helminth-infected
patients but recover if Treg cells are removed from the test cul-
tures.55 Similarly, BCG vaccination of helminth-infected subjects
elicits poor inflammatory cytokine responses to purified protein
derivative antigen in contrast to significant TGF-b production;
anthelmintic treatment reverses this scenario, suggesting that
interference with vaccine responses might be due to the presence
of immunosuppressive cytokines.56 Supporting this, a recent
study reported that tuberculosis-infected migrants in the United
Kingdom who were coinfected with helminths had higher Treg
cell frequencies than thosewith tuberculosis alone but that anthel-
mintic treatment decreased Treg cell numbers while increasing
TH1 effector populations.
57REGULATORY B CELLS, DENDRITIC CELLS, AND
MACROPHAGES IN HELMINTH INFECTION
Often overshadowed by their T-cell counterparts, regulatory B
(Breg) cells are also crucially important in control of the immune
responseduringhelminth infection.58Bcells fromHeligmosomoides
polygyrus–infected mice can suppress experimental autoimmune
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mice.59 Similarly, airway allergy can be suppressed by B cells
fromSchistosomamansoni–infectedmice, directly through their pro-
duction of IL-10 and indirectly by enhancing Treg cell activity.60
Importantly, the latter study found similar Breg phenotype cells in
schistosome-infected human subjects. High numbers of functional
IL-10 producing Breg cells were also found in patients withmultiple
sclerosis protected from relapse after acquiring intestinal helminth
infection compared with otherwise comparable uninfected pa-
tients.61 Along with Treg cell, Breg cells are strongly implicated in
the development of tolerance to allergens,62 and strategies to
encourage their expansion could increase the efficacy of allergen-
specific immunotherapy.
Dendritic cells (DCs) in patients with helminth infections have
been widely investigated for their propensity to induce TH2 re-
sponses in distinction tomicrobially stimulatedDCs, which effec-
tively drive TH1 and TH17 outcomes.
63,64 As yet, how DCs
recognize the presence of helminths is unresolved, although
certain key intracellular signals, such as the Kruppel-like factor
4 (KLF4), are now known to be essential for DCs to adopt the
pro-TH2 phenotype
65; beyond this stage, the mechanisms through
which DCs instruct TH2 development are similarly opaque but are
likely to include surface interactions, such as OX40/OX40 ligand
costimulation.66
The question of whether DCs in helminth-infectedmice aremore
tolerogenic and contribute to the expansion of Treg cells in vivo is
also of great interest. DCs recovered from helminth-infected mice
show altered phenotypes with, in the case ofH polygyrus infection,
expansion of CDllcloCD1032 DCs, which are preferential inducers
of Foxp31 Treg cells in vitro. In contrast, CD11chi DCs induced
stronger effector responses. In CD11cDTR mice diphtheria toxin
administration depleted only the CD11chi subset, greatly diminish-
ing the TH2 response, but spared the CD11c
lo population and the
Treg cell response they induced.67 In other studies intestinal DCs
from mice infected with the same parasite were able, when trans-
ferred into recombination-activating gene–deficient mice, to protect
recipients from T cell–mediated colitis.68
A more reductionist approach has tested DCs differentiated
in vitro from bonemarrow precursors with various helminth prod-
ucts before appraising their ability to induce regulatory cytokines
or cells fromT cells or frommice receiving a bolus of pulsedDCs.
A recurrent finding in these studies has been that helminth anti-
gens (eg, secreted products or egg extracts) block the Toll-like re-
ceptor–stimulated pathway that leads to IL-12 production and
TH1 induction.
69-71 In terms of in vivo immunoregulation, DCs
pulsed with Hymenolepis diminuta antigens are able to downmo-
dulate dinitrobenzene sulfonic acid colitis in recipient mice, and
CD41 T cells from those recipients can be further transferred to
new hosts and protect against colitis, requiring IL-10 production
for their effect.72 A substantial range of different helminth mole-
cules have now been reported tomodulate DC reactivity and func-
tion, as recently reviewed,64 promising a more mechanistic
understanding in the near future. In particular, the S mansoni
secreted protein v-1, a glycosylated T2 ribonuclease, is the first
helminth-derived molecule in which the mechanism of action of
DCs has been characterized. This glycoprotein is taken up by
mannose receptor binding to the glycan side chains, and once in-
side the cell, its ribonuclease activity degrades host mRNA,
ablating IL-12 production and encouraging TH2 differentiation.
73
Macrophages in patients with helminth infection are pro-
foundly altered in their profile, adopting an alternatively activatedphenotype (also termed M2) driven by the type 2 cytokines IL-4
and IL-13 and adopting a pattern of gene expression, metabolism,
and function markedly different from that of classically activated
(M1) macrophages, which respond to microbial stimulation
through Toll-like receptors.74 Signature protein products of the
M2 macrophage include arginase-1, RELM-a, and the
chitinase-like molecule Ym1.75 M2 macrophages are required
for effective immunity to some parasites (including H polygy-
rus76,77 in an arginase-1–dependent manner) and are instrumental
in repair and resolution of tissue damage caused, for example, by
migratory helminths.78 In this context helminth-stimulated
macrophages adopt an anti-inflammatory role with immunosup-
pressive characteristics, for example inhibiting T-cell prolifera-
tion,79 in part through expression of programmed death ligand
180 and enhancement of Treg cell differentiation through vitamin
A production by retinal dehydrogenase.81PROTECTION FROM ALLERGY, AUTOIMMUNITY,
AND ALLOGRAFT REJECTION
To investigate the immunomodulatory pathways used by
helminths, it is useful to consider the responses involved in their
ejection as the most likely targets for modulation. For example, in
the field of virology, the class I MHC presentation pathway is
crucial to orchestration of a productive antiviral CD8 T-cell
response: for almost every step in this pathway, a viral immuno-
modulator can be found that interferes in its normal functioning.82
Likewise, as the field of immunoparasitology matures, it is clear
that parasites have evolved strategies to modulate, subvert, or
evade each component of the immune response which might be
capable of eliminating them. Because it is often difficult to assess
the importance of immune pathways while under active suppres-
sion during parasitic infection, models of immunopathology have
been useful tools to assess modulation mediated by parasites or
their products.
It has been noted since 1968 that inflammatory disorders, such
as arthritis, are much less frequent in low-income countries with
high levels of parasite infection.83 Subsequent studies have further
established a reciprocal link between endemic helminth infection
and reduced prevalence of allergic reactivity and autoimmune an-
tibodies, aswell as increases in these immunologic indicators after
anthelmintic treatment.84-86 The downmodulation of immune
dysfunction in the presence of helminths depends on the exact
parasite species in question, as well as the intensity of infec-
tion,87,88 but has been reported across the spectrum of tropical en-
vironments using a range of different approaches (reviewed by
McSorley and Maizels1). It is likely that helminths impact at 2
levels: (1) modifying the level of host reactivity during develop-
ment of the infant immune system and (2) dampening immune re-
sponses in mature subjects whomight be exposed to helminths for
the first time in adult life.89 It is the latter setting that led to the pro-
posal that helminths or their products could be used as therapies
for inflammatory diseases in the parasite-free developed world.90
In settings of both allergy and autoimmunity, attenuation of
reactivity has been linked to downmodulatory cytokine produc-
tion, in particular IL-10 responses.84,86 Among the most remark-
able studies has been that of a cohort of patients with multiple
sclerosis in Argentina who unintentionally acquired gastrointes-
tinal helminth infections, with subsequent increased TGF-b and
IL-10 levels and higher Treg and Breg cell activity. Strikingly,
the infected patients enjoyed clinical remission from
TABLE I. Selected parasite-derived molecules with activity in immune-mediated diseases
Immune modulatory effect Example parasite product Mechanism of action
Disease models in which effi-
cacy is shown References
Suppression of innate and
adaptive immune cell
activation
A viteae ES-62 Nonconventional signaling
through TLR4, leading to
sequestration of PKC-a
Asthma, atopic dermatitis, SLE,
and arthritis
106-108
Suppression of antigen
presentation
S mansoni v-1 Degradation of DC mRNA,
preventing IL-12 secretion
NOD diabetes, metabolic
homeostasis
73, 105, 109
F hepatica FhHDM-1 Inhibition of vacuolar ATPase
resulting in reduced
endolysosomal acidification
Sepsis 110, 111
Cystatins:
A viteae Av17 (AvCystatin),
B malayi Bm-CPI-2,
N brasiliensis Nippocystatin
Inhibition of cysteine proteases
required for antigen
presentation; induction of IL-
10 through signaling events
downstream of an unknown
receptor (Av17)
Asthma, colitis 104,112-115
Suppression of ILC2 responses H polygyrus HES Suppression of ILC2-inducing
IL-33 responses
Asthma 103
Induction of Treg cells H polygyrus HES Secreted TGF-b mimic ligates
host TGF-b receptor
Asthma 45
S mansoni SEA/v-1 Induction of tolerogenic DCs,
which produce TGF-b and RA
Type I diabetes 46, 109
Bm-CPI-2, Brugia malayi cysteine protease inhibitor 2; FhHDM-1, Fasciola hepatica helminth defense molecule 1; HES, H polygyrus excretory secretory products; Hp-CPI, H
polygyrus cysteine protease inhibitor; ILC2, type 2 innate lymphoid cell; PKC, protein kinase C; RA, retinoic acid; SEA, Schistosoma mansoni soluble egg antigen; SLE, systemic
lupus erythematosus; TLR, Toll-like receptor.
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treatment experienced loss of regulatory cytokines and relapse
of disease.92
Experimental data echo and extend these findings in laboratory
models of allergic and autoimmune pathology.1,33,93,94 Helminth-
infected mice are less susceptible to airway inflammation after
allergen sensitization, and Treg cells from these mice can confer
protection against allergy when transferred to naive animals.52,53
Moreover, Breg cells,59,95 helminth-stimulated DCs,68 and regu-
latory macrophages96 are each able, in different settings, to confer
protection against pathology in recipient mice.
Reports such as these have fueled interest in the administration
of live helminths as therapies for a range of inflammatory
conditions from allergy, autism, autoimmunity, and colitis.90 Af-
ter some promising early studies,97 more recent trials have not
proved significant benefit.98,99 A number of reasons might under-
pin the perceived lack of efficacy of live helminth therapy.94 For
example, the human response to helminths is spectral, and only a
subset might gain benefit from live infection; each helminth spe-
cies inhabits a particular anatomic niche that might or might not
affect the site of inflammatory disease; the dynamics of any pro-
tective effect in terms of parasite dose and duration of infection
are unknown; and therapy of an established inflammatory disor-
der might require a particularly high parasite load or long-term
infection. For each of these reasons, a more analytic approach
of identifying immunomodulatory mechanisms and molecular
mediators from helminths is advocated as the best strategy for
developing new therapies inspired by the immunosuppressive ca-
pacities of parasites.100-102 By this means, individual molecular
products can be assessed, validated, and developed as defined
pharmaceuticals, which can then be delivered in a manner most
consistent with the indication in question. Most significantly,
this approach separates benefit from harm and removes the
need to introduce a potentially pathogenic parasite in the treat-
ment of disease.A schematic summary of some known helminth modulatory
pathways and targets for immune modulation is presented in
Fig 1, while a more detailed list of immunomodulatory effects of
parasite products with potential for use in immune-mediated dis-
ease is shown in Table I.45,46,73,103-115
As we elucidate mechanisms of immune-mediated parasite
ejection, we might appreciate new targets for immunomodula-
tion. For instance, eosinophils are required for ejection of many
parasites,116 and eosinophil accumulation is potently suppressed
by many parasite products in models of allergy.103,104,117-119
However, as yet, no parasite products have been identified that
act directly on this population. In subsequent sections wewill pro-
pose other likely targets of parasite immunomodulation.INTERACTIONS BETWEEN HELMINTHS AND
MICROORGANISMS
Intestinal helminths and those that occupy other mucosal sites,
such as the lung, cohabit with a spectrum of microbial organ-
isms.120-122 The entry of helminth parasites, such as H polygyrus,
Trichinella spiralis, or Trichuris muris, into the intestinal tracts of
mice significantly perturbs the commensal bacterial populations,
with important immunologic and metabolic consequences.123-126
In several studies helminth-infected mice show increase in Lacto-
bacillus species colonization, which in the case of H polygyrus
correlates with increased numbers of Treg cells; moreover, prior
administration of lactobacilli to mice renders them more suscep-
tible toH polygyrus infection, demonstrating a reciprocally bene-
ficial interaction between the metazoan and microbial species.124
Moreover, the transfer of intestinal contents from infected to un-
infected mice conferred immunomodulatory effects that reduced
allergic reactivity in naive recipients.127 A mechanistic insight
into how the microbiota might favor parasite establishment was
gained recently in studies of retinoic acid–related orphan receptor
gt–dependent T cells in the gut, which in response to microbial
FIG 1. Immune system–parasite interactions during helminth infections. A, Blockade of innate sensing and
alarmin production, such as inhibiting Toll-like receptor (TLR) responses of dendritic cells, thereby impair-
ing inflammatory TH1/TH17 development, and abrogating epithelial cell production of IL-33, thereby pre-
empting the type 2 response. ILC2, Type 2 innate lymphoid cell. B, Modulation of the adaptive immune
response, promoting Treg cell differentiation either directly through production of TGF-b–like mimics
(TGM) or indirectly by inducing host TGF-b and retinoic acid (RA) from DCs and macrophages. C,Modifica-
tion of bystander immune responses in the infected host.
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related orphan receptor gt–positive Treg cells, which together
repress TH2 immunity to H polygyrus.
128 It is presently unknown
whether these changes in the commensal population represent an
adaptation of commensals to the environment in helminth infec-
tion or are due to active modulation by helminth-secreted factors
(eg, secreted lysozymes).120HELMINTHS AND HOMEOSTASIS
Increasingly, regulation of metabolism and weight control is
recognized as an immunologic process,129,130 and hence it is
fascinating that helminth infections can protect against metabolic
disorders.131 In a seminal study,mice infected withNippostrongy-
lus brasiliensis and fed a high-fat diet were protected against
glucose intolerance through activation of adipose tissue eosino-
phils, which induced alternatively activated M2 macrophages.132
Similarly, not only S mansoni infection of mice but also adminis-
tration of soluble antigens from schistosome eggs, expanded ad-
ipose eosinophils and M2 macrophages.133 Interestingly, one of
the major molecular components of soluble antigens fromschistosome eggs, v-1, can itself protect against metabolic disor-
ders when administered to mice,105 opening up a biochemical
pathway that helminths can activate during infection that proves
beneficial to the host.HELMINTHS AND CANCER
There are many parallels between immune responses that result
in the progression of tumors and maintenance of parasite
infection. By better understanding immunosuppressed responses
to parasites and how these could be abrogated to expel the
pathogen, we can better understand anticancer responses and how
to bolster them for immunity. Parasitic infection could increase
carcinogenesis through associated low-grade chronic inflamma-
tory responses (in the absence of parasite ejection), secretion of
directly procarcinogenic factors, or suppression of immune
surveillance.134,135
Schistosoma haematobium infection results in deposition of
eggs in the bladder wall and is strongly linked to the development
of bladder cancer.136 Mouse models using egg injection into the
bladder wall have shown that egg deposition results in an
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ment136 and predisposing to tumorigenesis. In contrast, the trem-
atodeOpisthorchis viverrini resides in the bile duct and secretes a
granulin-like growth factor (Ov-GRN-1) that directly causes pro-
liferation of host cells and, with cofactors such as dietary carcin-
ogens, leads to transformation of bile duct cells and ultimately
cholangiocarcinoma.137,138 Likewise, the closely-related parasite
Clonorchis sinensis also encodes a granulin-like molecule that is
hypothesized to carry out the same function.139 Because these
parasites feed on bile duct cells, it has been proposed that by
encouraging cell proliferation, they are decreasing the damage
caused by their feeding (while increasing their food source),
with carcinogenesis being an unintended byproduct of this
pathway.140
The least well-studied mechanism of carcinogenesis by
parasite infection is suppression of immune surveillance, leading
to escape of mutated host cells, which would normally be
eliminated by the immune system. Myeloid-derived suppressor
cells accumulate during parasitic infections and are either
involved in parasite ejection141,142 or suppress antiparasite im-
mune responses,143 depending on the parasite species and chro-
nicity of infection. In antitumor responses myeloid-derived
suppressor cells are a well-characterized suppressive popula-
tion.144 Likewise, the expansion of Treg cells and alternative acti-
vation of macrophages during parasitic infection is associated
with suppression of antitumor immune responses.145 Together,
parasitic infection appears to result in a protumorigenic immune
milieu. Epidemiologic data in this area are presently lacking, and
the effects of parasitic infection in cancer progression requires
further attention.EPITHELIAL RESPONSES
The importance of epithelial barriers in initiation of immune
responses is now widely appreciated.146 In response to parasitic
infection or allergen administration, epithelial cell damage results
in release of damage-associated molecular patterns, such as ATP,
high mobility group box 1 (HMGB1), uric acid, and S100, as well
as proallergic alarmin cytokines, such as IL-33, IL-25, and thymic
stromal lymphopoietin, together with more generally inflamma-
tory cytokines, such as GM-CSF and IL-1a.147 The critical nature
of these responses can be seen in systems in which radioresistant
stromal cells (including epithelial cells) are specifically targeted
for knockdown of pattern recognition or cytokine receptors in
which allergic responses do not develop.148,149 Furthermore,
because the gut epithelium is critically involved in ejection of
parasitic infections (through increased mucus production and
epithelial cell turnover), the importance of the epithelium to the
antiparasite immune response cannot be overstated.150 Combined
with the intimate association between many helminths and the
epithelial barrier, this makes the epithelium a prime site for hel-
minth modulation.
Release of the alarmin cytokine IL-33 is a potent signal for
type 2 response initiation. Mice lacking the IL-33 signaling
pathway have abrogated type 2 responses to allergens and
parasites and are more susceptible to infection with Litomo-
soides sigmodontis,151 N brasiliensis,152 and T spiralis,153
whereas administration of exogenous IL-33 leads to ejection
of H polygyrus,154 N brasiliensis,155 Strongyloides venezuelen-
sis,156 and T muris.157 Thus the IL-33 pathway appears to bean ideal target for parasite immunomodulation to allow persis-
tence of infection. Indeed, the excretory/secretory products of
H polygyrus potently inhibit the IL-33 pathway, both by sup-
pressing IL-33 release103 and by suppressing expression of the
IL-33 receptor,158 resulting in reduced type 2 responses and
abrogated inflammation in a mouse model of asthma. Whether
these pathways of immunomodulation are common to many
intestinal helminths or unique to the chronically infective H pol-
ygyrus remains to be investigated.
In parallel to IL-33, IL-25 activates type 2 innate lymphoid
cells, potentiates type 2 immune responses, and is crucial for
ejection of parasites. Mice deficient in IL-25 or its receptor show
increased susceptibility to H polygyrus159,160 and N brasiliensis
primary or secondary infections.161 Chemosensory tuft cells of
the intestinal epithelium were recently identified as the major
source of IL-25 in the intestine during parasite infection.162-164
Remarkably, tuft cell–deficient mice show extremely abrogated
immunity to N brasiliensis infection, with all tuft cell–deficient
mice retaining productive infections up to 42 days after infec-
tion,162 whereas IL-25–deficient mice show only a slightly de-
layed response.161 Thus although tuft cells clearly have an
important role in producing IL-25, their antiparasite functions
must extend beyond this. As an emerging crucial element of the
antiparasite response, it appears likely that some parasites will
have developed mechanisms for modulating tuft cell responses
to allow their persistence in the host.HELMINTH VACCINES
As we have gained greater understanding of the complex
response required for ejection of parasites, we have attempted to
apply this to development of vaccines against helminth infections.
However, to date, no vaccines have been developed for human
helminth infections. The reasons for this include the subtle and
complex interplay of factors required for ejection,159 the potential
for collateral damage to the host, the risk of anaphylaxis in in-
fected populations,165 and the lack of defined single immunodo-
minant antigens.166 Finally, the competing immune regulatory
response, which is known to suppress bystander vaccinations,20
means that vaccination may only be a successful strategy in pop-
ulations cured of helminth infections by anthelmintics or in pre-
viously helminth-naive children.CONCLUSION
Parasites are subtle but powerful regulators of host immune
responses, suppressing some pathways of immune activation (eg,
DC antigen presentation, T-cell cytokine and B-cell antibody
production, and epithelial cell alarmin release), modulating other
pathways (eg, TH cell subset differentiation and B-cell isotype
switching), and inducing still others (eg, Treg and Breg cell differ-
entiation and tolerogenic DC responses). The immune pathways
required for induction, expansion, and maintenance of antipara-
site responses are still being elucidated. As we discover more
about how productive antiparasite responses are produced, we
are also discovering new pathways for immunomodulation of
these pathways by helminth infections and exploring new possi-
bilities for exploiting parasite molecules as therapies for inflam-
matory diseases.
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d What are the molecules secreted by parasites to induce
Treg and Breg cells?
d Do multiple parasite products suppress DC responses
through v-1–like ribonuclease activity? Is this unique to
schistosomes? Which other mechanisms are co-opted by
other parasites?
d Do parasite infections lead to reduced tumor immune sur-
veillance and increased cancer diagnoses?
d Do parasites interfere in epithelial cell responses beyond
IL-33?
d How can parasite-derived molecules be used to treat im-
munopathologies?
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